PATENT CLAIM ANALYSIS

Application Number: 16149420
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "093210"]

Abstract:
The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in  Homo sapiens  of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.

Claim (Index 4):
The pharmaceutical composition according to  claim 1 , wherein the polynucleotide is selected in the group consisting of RNA and DNA.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.82895
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12602736', '12745920', '14962337', '13909764', '13348435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7463516999517545
- 35 USC 102 Novelty (BERT): 0.5417451002315853
- Combined Prediction Score: 0.7258910399797377
- Mean Citation Score: 290.12198
- Max Citation Score: 377.54755
- Similarity Product: 266.6093188247502

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test